Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
28.18
+0.47 (1.70%)
Sep 18, 2025, 3:17 PM EDT - Market open
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $2.00M in the quarter ending June 30, 2025, a decrease of -9.51%. This brings the company's revenue in the last twelve months to $9.83M, down -21.09% year-over-year. In the year 2024, Tonix Pharmaceuticals Holding had annual revenue of $10.09M with 29.94% growth.
Revenue (ttm)
$9.83M
Revenue Growth
-21.09%
P/S Ratio
11.37
Revenue / Employee
$121,370
Employees
81
Market Cap
247.02M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.09M | 2.33M | 29.94% |
Dec 31, 2023 | 7.77M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TNXP News
- 7 hours ago - Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder - GlobeNewsWire
- 1 day ago - Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) - GlobeNewsWire
- 10 days ago - Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025 - GlobeNewsWire
- 21 days ago - Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025 - GlobeNewsWire
- 4 weeks ago - Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade) - Seeking Alpha
- 4 weeks ago - Tonix Secures Fibromyalgia Approval - What Investors Should Know - Seeking Alpha
- 4 weeks ago - US FDA approves Tonix Pharma's drug to manage pain related to chronic condition - Reuters
- 4 weeks ago - Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia - GlobeNewsWire